secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-108841
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched
--------------------------------------------------------------------------------

- Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.
- Cash, equivalents, marketable securities $229M; runway extended into 2028.
- New collaboration with Transition Bio for TDP-43 small molecules (ALS/FTD); upfront single-digit million, milestones up to $500M.
- Introduced ALPL-VYGR-NeuroShuttle nonviral platform; murine data shows >3 weeks brain expression.
- Novartis discontinues two discovery programs (rights return); Neurocrine milestone $3M expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465925108841/0001104659-25-108841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465925108841/vygr-20251110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer